Eisai and Merck provide update on sNDA for Lenvatinib
Eisai and Merck announced the FDA has extended the action date for the supplemental NDA or lenvatinib for the potential first-line treatment of patients with unresectable hepatocellular carcinoma. The agency expects to complete the review on or before Aug. 24, 2018. May 25, 2018